WHO Tiered-Effectiveness Counseling Is Rights-Based Family Planning

Contraceptive effectiveness is the leading characteristic for most women when choosing a method, but they often are not well informed about effectiveness of methods. Because of the serious consequences of “misinformed choice,” counseling should proactively discuss the most effective methods—long-acting reversible contraceptives and permanent methods—using the WHO tiered-effectiveness model.

Combination HIV prevention for female sex workers: what is the evidence?

Sex work occurs in many forms and sex workers of all genders have been affected by HIV epidemics worldwide. The determinants of HIV risk associated with sex work occur at several levels, including individual biological and behavioural, dyadic and network, and community and social environmental levels. Evidence indicates that effective HIV prevention packages for sex workers should include combinations of biomedical, behavioural, and structural interventions tailored to local contexts, and be led and implemented by sex worker communities. A model simulation based on the South African heterosexual epidemic suggests that condom promotion and distribution programmes in South Africa have already reduced HIV incidence in sex workers and their clients by more than 70%. Under optimistic model assumptions, oral pre-exposure prophylaxis together with test and treat programmes could further reduce HIV incidence in South African sex workers and their clients by up to 40% over a 10-year period. Combining these biomedical approaches with a prevention package, including behavioural and structural components as part of a community-driven approach, will help to reduce HIV infection in sex workers in different settings worldwide.

Invited commentary: consequential(ist) epidemiology: let's seize the day

Now is the time for the science of epidemiology to embrace its pragmatic roots. The article by Galea in this issue of the Journal (Am J Epidemiol. 2013;178(8):1185-1191) calls for us to become more "consequentialist." The Affordable Care Act allows us to access population-level databases from which we can examine how to deliver care more efficiently and cost-effectively. Asking the questions "so what" and "how much" will increase our relevance over the next decade.

Coverage, context and targeted prevention: optimising our impact

Development of efficacious interventions is only the first step in achieving population level impact. Efficacious interventions impact infection levels in the population only if they are implemented at the right scale. Coverage must be prioritised across subpopulations based on the diversity and clustering of infections and risk in society, and expanded rapidly without delay. It is important to prioritise those who are most likely to transmit infection first.

Defining and assessing evidence for the effectiveness of technical assistance in furthering global health

In an era when health resources are increasingly constrained, international organisations are transitioning from directly managing health services to providing technical assistance (TA) to in-country owners of public health programmes. We define TA as: 'A dynamic, capacity-building process for designing or improving the quality, effectiveness, and efficiency of specific programmes, research, services, products, or systems'. TA can build sustainable capacities, strengthen health systems and support country ownership. However, our assessment of published evaluations found limited evidence for its effectiveness. We summarise socio-behavioural theories relevant to TA, review published evaluations and describe skills required for TA providers. We explore challenges to providing TA including cost effectiveness, knowledge management and sustaining TA systems. Lastly, we outline recommendations for structuring global TA systems. Considering its important role in global health, more rigorous evaluations of TA efforts should be given high priority.

Condom use: still a sexual health staple

This article introduces and summarizes the contents of this special edition. Given the exceptional potential of condoms to avert epidemics of sexually transmitted infections and teen or unintended pregnancy - even in low-resource environments - this in-depth examination of current knowledge, practice, and issues with condoms and their use is an important asset for educators and practitioners worldwide.

Interventions to prevent sexually transmitted infections, including HIV infection

The Centers for Disease Control and Prevention (CDC) Sexually Transmitted Disease (STD) Treatment Guidelines were last updated in 2006. To update the "Clinical Guide to Prevention Services" section of the 2010 CDC STD Treatment Guidelines, we reviewed the recent science with reference to interventions designed to prevent acquisition of STDs, including human immunodeficiency virus (HIV) infection. Major interval developments include (1) licensure and uptake of immunization against genital human papillomavirus, (2) validation of male circumcision as a potent prevention tool against acquisition of HIV and some other sexually transmitted infections (STIs), (3) failure of a promising HIV vaccine candidate to afford protection against HIV acquisition, (4) encouragement about the use of antiretroviral agents as preexposure prophylaxis to reduce risk of HIV and herpes simplex virus acquisition, (5) enhanced emphasis on expedited partner management and rescreening for persons infected with Chlamydia trachomatis and Neisseria gonorrhoeae, (6) recognition that behavioral interventions will be needed to address a new trend of sexually transmitted hepatitis C among men who have sex with men, and (7) the availability of a modified female condom. A range of preventive interventions is needed to reduce the risks of acquiring STI, including HIV infection, among sexually active people, and a flexible approach targeted to specific populations should integrate combinations of biomedical, behavioral, and structural interventions. These would ideally involve an array of prevention contexts, including (1) communications and practices among sexual partners, (2) transactions between individual clients and their healthcare providers, and (3) comprehensive population-level strategies for prioritizing prevention research, ensuring accurate outcome assessment, and formulating health policy.

Reproductive choices for women with HIV

Access to reproductive health services for women with HIV is critical to ensuring their reproductive needs are addressed and their reproductive rights are protected. In addition, preventing unintended pregnancies in women with HIV is an essential component of a comprehensive prevention of mother-to-child transmission (PMTCT) programme. As a result, a call for stronger linkages between sexual and reproductive health and HIV policies, programmes and services has been issued by several international organizations. However, implementers of PMTCT and other HIV programmes have been constrained in translating these goals into practice. The obstacles include: (i) the narrow focus of current PMTCT programmes on treating HIV-positive women who are already pregnant; (ii) separate, parallel funding mechanisms for sexual and reproductive health and HIV programmes; (iii) political resistance from major HIV funders and policy-makers to include sexual and reproductive health as an important HIV programme component; and (iv) gaps in the evidence base regarding effective approaches for integrating sexual and reproductive health and HIV services. However, we now have a new opportunity to address these essential linkages. More supportive political views in the United States of America and the emergence of health systems strengthening as a priority global health initiative provide important springboards for advancing the agenda on linkages between sexual and reproductive health and HIV. By tapping into these platforms for advocating and by continuing to invest in research to identify integrated service delivery best practices, we have an opportunity to strengthen ties between the two synergistic fields.

From effectiveness to impact: contraception as an HIV prevention intervention

BACKGROUND

Most efforts to date to prevent mother-to-child transmission of HIV have focused on provision of antiretroviral prophylaxis to HIV-infected pregnant women. Increasing voluntary contraceptive use has been an underused approach, despite clear evidence that preventing pregnancies in HIV-infected women who do not wish to become pregnant is an effective strategy for reducing HIV-positive births. This paper reviews international, country and service delivery level opportunities for and obstacles to translating contraceptive efficacy into interventions that will have an impact on the effectiveness of HIV prevention.

METHODS

The integration of family planning services and HIV programmes as a potential intervention were specifically reviewed.

RESULTS AND CONCLUSIONS

Despite substantial policy support for the integration of family planning and HIV programmes, burgeoning resources for HIV ignore the potential impact of contraception on HIV prevention. Moreover, separate funding for these two programmes and the resulting vertical organisation of health ministries and service facilities undermine coordination between departments and limit providers' ability to address the contraceptive needs of HIV-positive clients. Projects integrating family planning and HIV services are being implemented, allowing for documentation of factors that facilitate or impede integrated service delivery. However, few have been evaluated to demonstrate impact on contraceptive uptake and HIV-positive births averted.

Contraception to prevent HIV-positive births: current contribution and potential cost savings in PEPFAR countries

OBJECTIVES

To estimate the number of HIV-positive births currently prevented by contraceptive use in the President's Emergency Plan for AIDS Relief (PEPFAR) focus countries and to estimate the first year cost savings to each country if unintended and unwanted HIV-positive births were prevented via contraceptive use rather than providing antiretroviral prophylaxis for HIV-positive pregnant women ("PMTCT services").

METHODS

Data from publicly available sources yielded estimates of (1) contraceptive and HIV prevalence; (2) the number of women of reproductive age; (3) the number of annual births to HIV-infected women; (4) the rates of pregnancy and vertical HIV transmission; (5) the proportions of unintended and unwanted births; and (6) the cost per HIV-positive birth averted by family planning and PMTCT services. The number of HIV-positive births currently averted by contraceptive use and the number of unwanted and unintended HIV-positive births are the product of these estimates. Cost savings are the difference in the costs of family planning and PMTCT services.

RESULTS

The annual number of unintended HIV-positive births currently averted by contraceptive use ranges from 178 in Guyana to over 120 000 in South Africa. The minimum annual cost savings to prevent just the unwanted HIV-positive births ranges from $26 000 in Vietnam to over $2.2 million in South Africa.

CONCLUSIONS

Contraception is already having an important effect on reducing the number of infant HIV infections. This contribution could be strengthened by additional efforts to provide contraception to HIV-infected women who do not wish to become pregnant. Moreover, the effect of contraception can be achieved at a cost savings compared with PMTCT services.

Are condoms the answer to rising rates of non-HIV sexually transmitted infections? Yes

Consistent condom use can reduce the spread of HIV, and Markus Steiner and Willard Cates believe condoms are the answer to other sexually transmitted infections. But Stephen Genuis argues that a more comprehensive approach is needed

Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial

OBJECTIVES

The objective of this trial was to investigate the safety and preliminary effectiveness of a daily dose of 300 mg of tenofovir disoproxil fumarate (TDF) versus placebo in preventing HIV infection in women.

DESIGN

This was a phase 2, randomized, double-blind, placebo-controlled trial.

SETTING

The study was conducted between June 2004 and March 2006 in Tema, Ghana; Douala, Cameroon; and Ibadan, Nigeria.

PARTICIPANTS

We enrolled 936 HIV-negative women at high risk of HIV infection into this study.

INTERVENTION

Participants were randomized 1:1 to once daily use of 300 mg of TDF or placebo.

OUTCOME MEASURES

The primary safety endpoints were grade 2 or higher serum creatinine elevations (>2.0 mg/dl) for renal function, grade 3 or 4 aspartate aminotransferase or alanine aminotransferase elevations (>170 U/l) for hepatic function, and grade 3 or 4 phosphorus abnormalities (<1.5 mg/dl). The effectiveness endpoint was infection with HIV-1 or HIV-2.

RESULTS

Study participants contributed 428 person-years of laboratory testing to the primary safety analysis. No significant differences emerged between treatment groups in clinical or laboratory safety outcomes. Study participants contributed 476 person-years of HIV testing to the primary effectiveness analysis, during which time eight seroconversions occurred. Two were diagnosed in participants randomized to TDF (0.86 per 100 person-years) and six in participants receiving placebo (2.48 per 100 person-years), yielding a rate ratio of 0.35 (95% confidence interval = 0.03-1.93), which did not achieve statistical significance. Owing to premature closures of the Cameroon and Nigeria study sites, the planned person-years of follow-up and study power could not be achieved.

CONCLUSION

Daily oral use of TDF in HIV-uninfected women was not associated with increased clinical or laboratory adverse events. Effectiveness could not be conclusively evaluated because of the small number of HIV infections observed during the study.

The multiple layers of prevention science research

A systematic framework for prevention science clinical research is described that explicitly links the identification of prevention needs to the implementation of research results in public health programs. The framework integrates five elements: advocacy and policy, community participation, prevention research, acceptability research, and operations and program development. These five elements are often viewed as disparate agendas, but an effective prevention science research enterprise requires that they be coordinated and integrated through all research stages--from the conceptual, to the experimental, and ultimately to the applied. Examples are provided of how this integration can be achieved from our experience in reproductive health and HIV prevention.

Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000

CONTEXT

In the United States, young people aged 15-24 represent 25% of the sexually experienced population. However, the incidence and prevalence of sexually transmitted diseases (STDs) among this age-group are unknown.

METHODS

Data from a variety of sources were used to estimate the incidence and prevalence of STDs among 15-24-year-olds in the United States in 2000. The quality and reliability of the estimates were categorized as good, fair or poor, depending on the quality of the data source.

RESULTS

Approximately 18.9 million new cases of STD occurred in 2000, of which 9.1 million (48%) were among persons aged 15-24. Three STDs (human papillomavirus, trichomoniasis and chlamydia) accounted for 88% of all new cases of STD among 15-24-year-olds.

CONCLUSIONS

These estimates emphasize the toll that STDs have on American youth. More representative data are needed to help monitor efforts at lowering the burden of these infections.

Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000

CONTEXT

In the United States, young people aged 15-24 represent 25% of the sexually experienced population. However, the incidence and prevalence of sexually transmitted diseases (STDs) among this age-group are unknown.

METHODS

Data from a variety of sources were used to estimate the incidence and prevalence of STDs among 15-24-year-olds in the United States in 2000. The quality and reliability of the estimates were categorized as good, fair or poor, depending on the quality of the data source.

RESULTS

Approximately 18.9 million new cases of STD occurred in 2000, of which 9.1 million (48%) were among persons aged 15-24. Three STDs (human papillomavirus, trichomoniasis and chlamydia) accounted for 88% of all new cases of STD among 15-24-year-olds.

CONCLUSIONS

These estimates emphasize the toll that STDs have on American youth. More representative data are needed to help monitor efforts at lowering the burden of these infections.

Dual protection against unintended pregnancy and sexually transmitted infections: what is the best contraceptive approach?

In the midst of the global epidemics of both unintended pregnancy and sexually transmitted infection, contraceptive options that provide dual protection are ideal. However, those contraceptives with the best record of preventing pregnancy under typical use conditions (sterilization, hormonal methods, intrauterine devices) provide little if any protection against sexually transmitted infection. Alternatively, barrier contraceptive methods (specifically, condoms), which can reduce risks of many sexually transmitted infections, are associated with relatively higher pregnancy rates for most users than other contraceptives. This situation has produced a dilemma for those wishing to promote dual protection: whether to advocate use of two methods (one primarily to prevent pregnancy and the other primarily to prevent infections) or whether to emphasize use of condoms for both purposes. Data comparing these two approaches are limited and often contradictory. We discuss the underlying concepts of exposure to both pregnancy and infection, provide a broad overview of the effectiveness of contraceptive methods against these two conditions, present approaches to optimize dual protection, and propose several new directions for necessary research. In the absence of evidence-based recommendations, we believe clinicians should assist clients in assessing their likelihood of exposure to infection, either by prevalence of sexually transmitted infection in the community or by the specific risk factors of the client. If exposure is likely, particularly to the more serious infections such as human immunodeficiency virus, the one-method approach should be given greater weight. However, in settings where unintended pregnancy is the greater concern, emphasizing the two-methods approach as a first option may be appropriate.